BioCentury
ARTICLE | Clinical News

argenx reports Phase I/II cancer data of CD70 mAb

December 15, 2017 3:48 AM UTC

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported data from two Phase I/II trials of ARGX-110 at the American Society of Hematology (ASH) meeting in Atlanta.

Preliminary data from six evaluable patients with newly diagnosed acute myelogenous leukemia (AML) who were ineligible for intensive chemotherapy in a Phase I/II study showed that ARGX-110 plus Vidaza azacitidine led to three complete remissions, one complete remission with incomplete blood count recovery and two partial responses. The open-label, Swiss trial is enrolling about 36 patients with newly diagnosed AML or high risk myelodysplastic syndrome (MDS). The primary endpoints are dose-limiting toxicities (DLTs) and overall response rate (ORR)...

BCIQ Target Profiles

CD70 (CD27L)